These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

497 related articles for article (PubMed ID: 10808205)

  • 1. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serial and quantitative analysis of mixed hematopoietic chimerism by PCR in patients with acute leukemias allows the prediction of relapse after allogeneic BMT.
    Bader P; Beck J; Frey A; Schlegel PG; Hebarth H; Handgretinger R; Einsele H; Niemeyer C; Benda N; Faul C; Kanz L; Niethammer D; Klingebiel T
    Bone Marrow Transplant; 1998 Mar; 21(5):487-95. PubMed ID: 9535041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
    Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
    Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of CBFbeta/MYH11 fusion transcripts in patients with inv(16) acute myeloid leukemia after allogeneic bone marrow or peripheral blood progenitor cell transplantation.
    Elmaagacli AH; Beelen DW; Kroll M; Trzensky S; Stein C; Schaefer UW
    Bone Marrow Transplant; 1998 Jan; 21(2):159-66. PubMed ID: 9489633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engraftment and chimerism, particularly of T- and B-cells, in children undergoing allogeneic bone marrow transplantation.
    Winiarski J; Mattsson J; Gustafsson A; Wester D; Borgström B; Ringdén O; Ljungman P; Dalianis T
    Pediatr Transplant; 1998 May; 2(2):150-6. PubMed ID: 10082448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
    Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
    Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of hematopoietic chimerism in patients with acute leukemia after allogeneic bone marrow transplantation: a prospective study.
    Choi SJ; Lee KH; Lee JH; Kim S; Chung HJ; Lee JS; Kim SH; Park CJ; Chi HS; Kim WK
    Bone Marrow Transplant; 2000 Aug; 26(3):327-32. PubMed ID: 10967574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chimerism after allogeneic hematopoietic cell transplantation in childhood acute lymphoblastic leukemia.
    Ramírez M; Díaz MA; García-Sánchez F; Velasco M; Casado F; Villa M; Vicario JL; Madero L
    Bone Marrow Transplant; 1996 Dec; 18(6):1161-5. PubMed ID: 8971389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences.
    Koldehoff M; Steckel NK; Hlinka M; Beelen DW; Elmaagacli AH
    Am J Hematol; 2006 Oct; 81(10):735-46. PubMed ID: 16838323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorescent in situ hybridization on flow-sorted cells as a tool for evaluating minimal residual disease or chimerism after allogenic bone marrow transplantation.
    Cotteret S; Belloc F; Boiron JM; Bilhou-Nabera C; Dumain P; Boyer C; Lacombe F; Reiffers J; Bernard P
    Cytometry; 1998 Oct; 34(5):216-22. PubMed ID: 9822307
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCR detection of clonal IgH and TCR gene rearrangements at the end of induction as a non-remission criterion in children with ALL: comparison with standard morphologic analysis and risk group classification.
    Scrideli CA; Queiroz RG; Bernardes JE; Valera ET; Tone LG
    Med Pediatr Oncol; 2003 Jul; 41(1):10-6. PubMed ID: 12764736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of clinical utility of minimal residual disease detection in allogeneic stem cell recipients with childhood acute lymphoblastic leukemia: multi-institutional collaborative study in Japan.
    Imashuku S; Terui K; Matsuyama T; Asami K; Tsuchiya S; Ishii E; Kawa K; Kosaka Y; Eguchi H; Tsuchida M; Ikuta K; Kato S; Koizumi S; Okamura J; Morimoto A; Hibi S; Hamaoka K;
    Bone Marrow Transplant; 2003 Jun; 31(12):1127-35. PubMed ID: 12796792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Becks HW; Mobascher A; Stockova J; Trzensky S; Opalka B; Schaefer UW
    Bone Marrow Transplant; 1996 Aug; 18(2):397-403. PubMed ID: 8864452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.